The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
- 1 April 2021
- journal article
- research article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 18 (2), 1175-1187
- https://doi.org/10.1007/s13311-021-01005-w
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceuticals U.S.A.
This publication has 42 references indexed in Scilit:
- Electrocortical changes associated with minocycline treatment in fragile X syndromeJournal of Psychopharmacology, 2013
- FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and AutismCell, 2011
- Profiling Fragile X Syndrome in males: Strengths and weaknesses in cognitive abilitiesResearch in Developmental Disabilities, 2010
- Advances in the Treatment of Fragile X SyndromePEDIATRICS, 2009
- Chirp-evoked potentials in the awake and anesthetized rat. A procedure to assess changes in cortical oscillatory activityExperimental Neurology, 2008
- Potentials evoked by chirp-modulated tones: a new technique to evaluate oscillatory activity in the auditory pathwayClinical Neurophysiology, 2004
- FMR1 and the fragile X syndrome: Human genome epidemiology reviewGenetics in Medicine, 2001
- Development and Behavior of Male Toddlers With Fragile X SyndromeJournal of Early Intervention, 2001
- Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: A preliminary reportAmerican Journal of Medical Genetics, 1999
- Cyclic AMP metabolism in fragile X syndromeAnnals of Neurology, 1992